Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.
about
CAR models: next-generation CAR modifications for enhanced T-cell functionCAR T Cell Therapy: A Game Changer in Cancer TreatmentRecent advances in T-cell engineering for use in immunotherapyAn Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersT cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.CAR T-cell immunotherapy: The path from the by-road to the freeway?Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Engineering Chimeric Antigen Receptors.A TCR-based Chimeric Antigen Receptor.T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy.Fine-tuning the CAR spacer improves T-cell potency.Practical considerations for chimeric antigen receptor design and delivery.Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains.Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells.Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene.The development of CAR design for tumor CAR-T cell therapy.Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d TargetingEfficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing
P2860
Q26745600-5640FF29-556A-4831-BE43-0293AD0EA556Q26822769-E3AD9D36-7261-412F-B894-38D4778CE55EQ28080312-743B168B-58B0-48DA-89B6-DF8E4D53F9C9Q28551080-1CF38AC7-20BB-4A0D-AC1F-61DE86B6B46BQ33632100-5541C10D-46F3-41C7-A69A-448B0452924CQ34553167-715B7744-DD7B-4D29-8E80-0A2CC5381046Q38632105-2F222DCF-5B07-4C4D-97BE-F00CD4F42533Q38694036-F7D958AD-1CFA-4BF0-8875-EB8A6F881C16Q38783833-2BD36603-E0E6-4A8B-AB3A-3AE2E585D663Q38786626-D8D02D27-9C80-4D2B-B3B2-E674A981BDA0Q38839878-74C5A4F1-4AE5-4D92-8FD8-88D2D2251725Q39246685-15F39B27-6004-43F8-BA29-91F3A6571C51Q39276909-9E8A997E-4803-44A1-A134-8AEF11C54CA0Q41631133-882BDD84-1D16-4D76-B9B7-F44B4BA70AA3Q42333881-9C9D480E-08FA-4E51-BBBD-EAA6579FBC8EQ42967415-E8F65415-F9C5-4D21-9ECE-6DB4BBDA50C8Q45868559-CC2479ED-3100-4753-8C0B-7327F9952F2DQ50025140-02EE443A-B789-41C4-B80A-4360694711E9Q52568130-EC384B7F-EADE-4568-A25A-6C31162041BBQ52606153-B9E16F22-4084-48D5-81A5-07E17008A06BQ52641562-502C82E5-54B9-4B48-A18C-8B82B546AFC0Q57293724-7AB4B0F2-5CC8-4886-BD6B-5E975A50FB57Q59125585-E47CFEE6-A468-43D8-BB78-A84F40612F69
P2860
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Inclusion of an IgG1-Fc spacer ...... ls in a xenograft mouse model.
@en
type
label
Inclusion of an IgG1-Fc spacer ...... ls in a xenograft mouse model.
@en
prefLabel
Inclusion of an IgG1-Fc spacer ...... ls in a xenograft mouse model.
@en
P2093
P2860
P356
P1433
P1476
Inclusion of an IgG1-Fc spacer ...... ls in a xenograft mouse model.
@en
P2093
A Kristian
G Kvalheim
H Almåsbak
J T Andersen
L A Munthe
P2860
P2888
P304
P356
10.1038/GT.2015.4
P577
2015-02-05T00:00:00Z